Entertainment
MediLink presents YL201 (B7H3 ADC) at ESMO 2024, with over 6-months PFS in SCLC, and showing pan-tumor benefits
The first publication of clinical data for YL201, featured in an oral presentation at ESMO 2024. Encouraging antitumor activity of YL201 in multiple solid tumor types, including SCLC, NPC, and wild-type NSCLC, from Phase I escalation and expansion re
By: en_prnasisa
- Sep 14 2024
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS